Goldman Sachs Group set a CHF 325 price target on Roche (VTX:ROG) in a research note issued to investors on Thursday. The brokerage currently has a buy rating on the healthcare company’s stock.

ROG has been the subject of several other research reports. Deutsche Bank set a CHF 255 target price on shares of Roche and gave the stock a neutral rating in a report on Monday, September 11th. Berenberg Bank set a CHF 260 target price on shares of Roche and gave the stock a neutral rating in a report on Tuesday, October 24th. J P Morgan Chase & Co reaffirmed a buy rating on shares of Roche in a report on Monday, October 9th. Morgan Stanley set a CHF 260 target price on shares of Roche and gave the stock a neutral rating in a report on Friday, October 6th. Finally, Jefferies Group set a CHF 295 target price on shares of Roche and gave the stock a buy rating in a report on Monday, October 16th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average target price of CHF 261.32.

Roche (ROG) opened at CHF 240.50 on Thursday. Roche has a 1-year low of CHF 219.10 and a 1-year high of CHF 273.

COPYRIGHT VIOLATION WARNING: “Goldman Sachs Group Analysts Give Roche (ROG) a CHF 325 Price Target” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.watchlistnews.com/goldman-sachs-group-analysts-give-roche-rog-a-chf-325-price-target/1754808.html.

Roche Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.